A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis
This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.
This is a Phase II, randomized, double-blind, placebo-controlled study to determine the effect of SCD-044 in subjects with moderate to severe atopic dermatitis.
Inclusion Criteria:
Exclusion Criteria:
Female Subjects who are pregnant, nursing, or planning to become pregnant during study participation or within 6 months of completing the study.
Known organ complications of Diabetes mellitus such as reduced renal function, significant retinal pathology or neuropathy.
History or presence of uveitis
-
Tbilisi, 144, Georgia
Poznan, 60-309, Poland
Warsaw, 04-141, Poland